This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Take the CME quiz:
 Vol. 22 No. 5, November 2009
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Li, S. C.
PubMed
Right arrow Articles by Li, S. C.

AAP Grand Rounds 22:55 (2009)
© 2009 American Academy of Pediatrics

RHEUMATOLOGY

Polyarticular JIA: The Elusive Quest for Disease Remission

Source: Ringold S, Seidel KD, Koepsell TD, et al. Inactive disease in polyarticular juvenile idiopathic arthritis: current patterns and associations. Rheumatol. 2009;48(8):972–977; doi:10.1093/rheumatology/kep144[Abstract/Free Full Text]

The first 20% of the full text of this article appears below.


PICO

Question: Among children with polyarticular JIA, what factors are associated with achievement of inactive disease or remission?

Question type: Prognosis

Study design: Retrospective review

 

Investigators from Seattle Children’s Hospital performed a retrospective record review of children with polyarticular (five or more joints) juvenile idiopathic arthritis (JIA) followed at their institution between 2000 and 2006 to determine the frequency of and factors associated with achievement of inactive disease (ID) and remission. ID was defined according to a previously published scale, utilizing both clinical and laboratory parameters.2 The duration of ID was specified as from the first clinic visit with ID until the first clinic visit where the patient was found to have active disease. Clinical remission on medicines was defined as six months of ID while on any anti-arthritis or uveitis medicines, and clinical remission was defined as one year of ID while not receiving any anti-arthritis or uveitis medicines. Patients were eligible for . . . [Full Text of this Article]

Suzanne C. Li, MD, PhD, FAAP
Pediatrics, Joseph M. Sanzari Children’s Hospital, HUMC, Hackensack, NJ